Biomarkers in Atopic Dermatitis and Psoriasis
Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment.
Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems.
BIOMAP will examine the causes and mechanisms of these conditions by identifying the biomarkers responsible for the variation in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics.
60 months
12 countries
21.2 Mio €
Areas of focus
Network
Molecular Profiling
Diseases
Database
Voices of BIOMAP
“By joining the expertise from academia and pharmaceutical industry, and by analysing a collection of harmonised clinical and molecular data from nearly a million sufferers, unprecedented in scale and depth, ranging from multi-dimensional datasets on single cells (skin and blood) through to whole populations, atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”
Prof. Stephan Weidinger
Christian-Albrechts-Universität zu Kiel
Coordinator
“BIOMAP presents a major opportunity to improve the lives of people with skin disease – we need information on why and who is going to develop severe disease, and also new approaches to treatment. Involving a Patient Advisory Group puts the needs of the patients at the heart of the project from the very beginning. By providing a European-wide platform for collaboration, BIOMAP will enable sharing of know-how and data about atopic dermatitis and psoriasis so that we can all work together like never before.”
Helen McAteer
Chief Executive of the Psoriasis Association
BIOMAP Patient Advisory Group
“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases.”
Dr Witte Koopmann
Co-project lead
LEO Pharma
“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene.”
Professor Catherine Smith
Co-coordinator
King’s College London
“By understanding these diseases as comprehensively as possible, any molecularly defined endotypes we will find will help to drive the next generation of precision therapies that can improve the lives of patients.”
Dr Paul Bryce
Project lead
Sanofi